StocksFundsScreenerSectorsWatchlists
BCYC

BCYC - Bicycle Therapeutics Ltd Stock Price, Fair Value and News

24.90USD+0.35 (+1.43%)Market Closed

Market Summary

BCYC
USD24.90+0.35
Market Closed
1.43%

BCYC Stock Price

View Fullscreen

BCYC RSI Chart

BCYC Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-5.85

Price/Sales (Trailing)

39.17

EV/EBITDA

-3.31

Price/Free Cashflow

-16.62

BCYC Price/Sales (Trailing)

BCYC Profitability

EBT Margin

-664.32%

Return on Equity

-48.71%

Return on Assets

-30.35%

Free Cashflow Yield

-6.02%

BCYC Fundamentals

BCYC Revenue

Revenue (TTM)

27.0M

Rev. Growth (Yr)

67.38%

Rev. Growth (Qtr)

-0.39%

BCYC Earnings

Earnings (TTM)

-180.7M

Earnings Growth (Yr)

-63.78%

Earnings Growth (Qtr)

1.6%

Breaking Down BCYC Revenue

Last 7 days

4.8%

Last 30 days

1.1%

Last 90 days

37.7%

Trailing 12 Months

21.2%

How does BCYC drawdown profile look like?

BCYC Financial Health

Current Ratio

8.08

Debt/Equity

0.08

Debt/Cashflow

-1.97

BCYC Investor Care

Shares Dilution (1Y)

42.04%

Diluted EPS (TTM)

-5.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202315.5M22.5M24.8M27.0M
202213.7M16.3M15.0M14.5M
202111.1M11.3M11.8M11.7M
20208.5M8.6M11.8M10.4M
201910.7M10.6M9.6M13.8M
20183.3M4.6M5.9M7.1M
20170002.1M

Tracking the Latest Insider Buys and Sells of Bicycle Therapeutics Ltd

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
sands stephen h.
acquired
-
-
12,000
-
Feb 06, 2024
arroyo santiago
acquired
-
-
21,660
chief development officer
Jan 03, 2024
crockett nigel
sold
-46,252
17.5
-2,643
chief business officer
Jan 03, 2024
lee kevin
sold
-152,302
17.5
-8,703
chief executive officer
Jan 03, 2024
milnes alistair
sold
-46,252
17.5
-2,643
chief operating officer
Jan 03, 2024
thompson travis alvin
sold
-10,570
17.5
-604
chief accounting officer
Jan 03, 2024
skynner michael
sold
-46,252
17.5
-2,643
chief technology officer
Jan 03, 2024
keen nicholas
sold
-46,200
17.5
-2,640
chief scientific officer
Jan 02, 2024
thompson travis alvin
acquired
-
-
16,000
chief accounting officer
Jan 02, 2024
legault pierre
acquired
-
-
12,000
-

1–10 of 50

Which funds bought or sold BCYC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 27, 2024
NOMURA HOLDINGS INC
unchanged
-
-804,000
7,232,000
0.02%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
136,684
136,684
-%
Feb 21, 2024
Raleigh Capital Management Inc.
sold off
-100
-3,717
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-53.32
-6,909,000
5,006,000
-%
Feb 15, 2024
Legal & General Group Plc
added
43.63
539,431
2,399,790
-%
Feb 15, 2024
WEXFORD CAPITAL LP
new
-
630,612
630,612
0.14%
Feb 15, 2024
Virtus ETF Advisers LLC
added
66.59
37,157
111,590
0.07%
Feb 15, 2024
HORIZON KINETICS ASSET MANAGEMENT LLC
reduced
-4.03
-41,070
260,280
-%
Feb 15, 2024
BARCLAYS PLC
added
8,847
268,000
272,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
68.00
507,812
1,499,740
-%

1–10 of 44

Are Funds Buying or Selling BCYC?

Are funds buying BCYC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BCYC
No. of Funds

Unveiling Bicycle Therapeutics Ltd's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
jefferies financial group inc.
165%
1,948,000
SC 13G
Feb 14, 2024
deep track capital, lp
9.25%
3,490,506
SC 13G/A
Feb 14, 2024
paradigm biocapital advisors lp
9.8%
3,707,001
SC 13G/A
Feb 14, 2024
ridgeback capital investments l.p.
2.2%
844,235
SC 13G/A
Feb 12, 2024
janus henderson group plc
0.0%
0
SC 13G/A
Feb 12, 2024
baker bros. advisors lp
12.8%
4,823,598
SC 13G
Jul 20, 2023
gsk plc
4.4%
1,529,561
SC 13D/A
Feb 24, 2023
paradigm biocapital advisors lp
5.4%
1,610,665
SC 13G
Feb 14, 2023
logos global management lp
4.8%
1,435,000
SC 13G/A
Feb 14, 2023
ridgeback capital investments l.p.
7.6%
2,264,801
SC 13G/A

Recent SEC filings of Bicycle Therapeutics Ltd

View All Filings
Date Filed Form Type Document
Mar 21, 2024
3
Insider Trading
Mar 21, 2024
4
Insider Trading
Feb 21, 2024
3
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 20, 2024
10-K
Annual Report
Feb 20, 2024
8-K
Current Report
Feb 20, 2024
S-8
Employee Benefits Plan
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Bicycle Therapeutics Ltd)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.7B
6.8B
10.47% -29.37%
-8.64
5.95
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.8B
1.8B
-5.20% -21.33%
-42.76
10.3
76.23% 61.08%
16.5B
2.4B
-4.27% -3.75%
98.3
6.81
15.42% 18.43%
12.8B
3.7B
-5.97% -18.88%
21.4
3.46
8.87% 75.42%
MID-CAP
7.1B
396.6M
-14.15% -6.74%
-13.41
17.87
425.83% 18.94%
5.4B
-
-9.06% 107.52%
-8.32
60.35
54.84% -34.79%
3.8B
270.6M
1.09% 28.79%
-15.8
13.97
440.80% -27.84%
3.5B
240.7M
-9.47% 17.74%
-11.94
14.72
-1.03% -92.09%
3.0B
726.4M
-25.38% 1.37%
-49.71
4.19
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
13.53% -1.12%
26.31
4.72
85.90% -14.05%
669.0M
983.7M
-9.64% -20.86%
-1.23
0.68
-50.36% 17.16%
411.7M
881.7K
52.39% 472.85%
-9.23
466.16
-77.61% -5.33%
324.4M
4.9M
76.14% 20.49%
-2.4
66.66
-54.97% 51.72%
14.1M
2.1M
238.33% 93.33%
-0.52
2.14
-13.45% 66.37%

Bicycle Therapeutics Ltd News

Latest updates
Defense World • 23 Mar 2024 • 02:26 pm
CNN • 07 Mar 2024 • 10:38 pm
TipRanks • 20 Feb 2024 • 08:00 am
Seeking Alpha • 13 Feb 2024 • 08:00 am
StockNews.com • 10 months ago

Bicycle Therapeutics Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-0.4%5,331,0005,352,00011,397,0004,896,0003,185,0003,040,0004,378,0003,860,0003,771,0004,333,0001,785,0001,808,0003,848,0003,842,0001,571,0001,129,0005,281,000614,0001,522,0006,384,0001,057,000
Operating Expenses6.1%59,566,00056,149,00054,508,00046,699,00035,396,00032,799,00031,678,00031,243,00021,794,50018,627,00019,062,00017,832,00020,907,00014,517,00014,154,00012,772,00010,045,00010,867,0009,510,0009,678,0008,599,000
  S&GA Expenses-8.7%14,869,00016,281,00014,788,00014,488,00010,677,00010,047,00011,824,00016,959,0008,840,5008,114,0007,340,0008,139,00010,851,5007,154,0006,196,0004,998,0003,396,0004,789,0002,973,0003,402,0002,106,000
  R&D Expenses12.1%44,697,00039,868,00039,720,00032,211,00024,719,00022,752,00019,854,00014,284,00012,954,00010,513,00011,722,0009,693,00010,056,0007,363,0007,958,0007,774,0006,649,0006,078,0006,537,0006,276,0006,493,000
EBITDA Margin-3.1%-6.28-6.09-5.89-7.60-7.41-6.42-5.14-5.47-5.48-5.55-5.40-4.98-4.81--------
Interest Expenses0.7%820,000814,000821,000808,000826,000817,000883,000818,000820,000823,000819,000522,000---------
Income Taxes-86.3%315,5002,300,000-517,000-600,000-429,500-238,000-447,000-400,000-755,500-400,000-200,000-300,000-55,000-465,000-97,000-100,000-138,000-331,000135,00080,000-
Earnings Before Taxes-2.4%-48,779,000-47,626,000-43,120,000-39,682,000-30,398,000-28,585,000-27,275,000-27,983,000-18,785,000-15,093,000-18,073,000-16,531,000-17,488,000-10,603,000-12,212,000-11,431,000-4,544,000-9,813,000-10,082,000-6,423,000-6,641,000
EBT Margin-2.6%-6.64-6.48-6.30-8.13-7.90-6.82-5.45-5.81-5.85-5.71-5.56-5.13-4.98--------
Net Income1.6%-49,099,000-49,898,000-42,603,000-39,064,000-29,978,000-28,347,000-26,828,000-27,564,000-18,037,000-14,678,000-17,913,000-16,191,000-17,433,000-10,138,000-12,115,000-11,324,000-4,406,000-9,482,000-10,217,000-6,503,000-6,641,000
Net Income Margin-2.9%-6.70-6.51-6.22-8.01-7.79-6.70-5.33-5.69-5.71-5.62-5.47-5.05-4.91--------
Free Cashflow-3000.1%-47,339,000-1,527,00033,819,000-48,510,000-31,757,000-8,855,000-33,330,000-31,156,000-11,502,00021,549,000-12,541,000-14,330,000-17,101,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-6.8%59563945442941141744546048028122622416117011912911011612682.00
  Current Assets-6.8%56260340838136938140843045927321821515616411312310411012077.00
    Cash Equivalents-8.0%52657234029433936137340743926019919613615097.0011092.0096.0010963.00
  Net PPE-6.9%15.0016.0018.0018.0019.0016.0017.009.003.002.002.003.002.002.002.002.002.002.002.002.00
Liabilities0.8%22422323418614012813412913411184.0082.0066.0061.0048.0047.0017.0021.0022.0029.00
  Current Liabilities-0.3%70.0070.0072.0053.0053.0042.0041.0035.0036.0030.0023.0021.0023.0017.0017.0016.009.009.009.009.00
  Long Term Debt0.3%31.0031.0031.0030.0030.0030.0030.0030.0030.0030.0030.0029.0015.0014.00------
    LT Debt, Non Current0.3%31.0031.0031.0030.0030.0030.0030.0030.0030.0030.0030.0029.0015.0014.00------
Shareholder's Equity-10.8%37141622024327128931133034617114214295.0011071.0082.0093.0095.00105-
  Retained Earnings-10.6%-511-462-412-370-331-301-272-245-218-200-185-167-151-134-123-111-100-96.14-86.66-69.94
  Additional Paid-In Capital0.9%8838756336136015905845785683743313132502461991971951941932.00
Shares Outstanding0.1%42.0042.0031.0030.0030.0030.0030.0030.0025.0024.0024.0022.0019.00-------
Float---767---490---718---190---114-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-4513.5%-47,288-1,02534,096-46,411-30,309-5,871-23,531-26,400-10,43521,718-12,370-13,707-16,617-9,985-12,34921,162-4,919-10,885-7,608-5,201-8,854
  Share Based Compensation5.1%7,8127,4308,1939,0425,5405,3685,67310,1982,9992,6882,5753,8211,5641,5101,3192,1211,083819905276207
Cashflow From Investing89.8%-51.00-502-277-2,099-1,448-2,984-9,799-4,756-1,067-169-171-623-484-95.00-301-320-391-283-463-418-410
Cashflow From Financing-99.8%386234,63112,2922,7185,888159195450190,66440,45015,55274,0591,74461,08710.002.00122-81159,09534.00-

BCYC Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss   
Collaboration revenues$ 26,976$ 14,463$ 11,697
Operating expenses:   
Research and development156,49681,60944,880
General and administrative60,42649,50732,435
Total operating expenses216,922131,11677,315
Loss from operations(189,946)(116,653)(65,618)
Other income (expense):   
Interest income14,0025,756120
Interest expense(3,263)(3,344)(2,984)
Total other income (expense), net10,7392,412(2,864)
Net loss before income tax provision(179,207)(114,241)(68,482)
Provision for (benefit from) income taxes1,457(1,524)(1,663)
Net loss$ (180,664)$ (112,717)$ (66,819)
Net loss per share, basic$ (5.08)$ (3.80)$ (2.67)
Net loss per share, diluted$ (5.08)$ (3.80)$ (2.67)
Weighted average ordinary shares outstanding, basic35,592,36229,660,65925,061,734
Weighted average ordinary shares outstanding, diluted35,592,36229,660,65925,061,734
Comprehensives loss:   
Net Income (Loss)$ (180,664)$ (112,717)$ (66,819)
Other comprehensive (loss) income:   
Foreign currency translation adjustment(1,691)3,775(195)
Total comprehensive loss$ (182,355)$ (108,942)$ (67,014)

BCYC Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 526,423$ 339,154
Accounts receivable02,045
Prepaid expenses and other current assets11,4069,022
Research and development incentives receivable24,03919,162
Total current assets561,868369,383
Property and equipment, net14,51519,110
Operating lease right-of-use assets13,16913,658
Other assets5,7928,458
Total assets595,344410,609
Current liabilities:  
Accounts payable13,0506,472
Accrued expenses and other current liabilities31,50926,452
Deferred revenue, current portion24,97820,418
Total current liabilities69,53753,342
Long-term debt, net of discount30,69830,315
Operating lease liabilities, net of current portion9,38210,885
Deferred revenue, net of current portion110,21641,455
Other longterm liabilities4,5793,829
Total liabilities224,412139,826
Commitments and contingencies (Note 11)
Shareholders' equity:  
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 59,612,613 and 57,820,181 shares authorized at December 31, 2023 and December 31, 2022, respectively; 42,431,766 and 29,873,893 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively550387
Additional paid-in capital883,446601,105
Accumulated other comprehensive (loss) income(1,304)387
Accumulated deficit(511,760)(331,096)
Total shareholders' equity370,932270,783
Total liabilities and shareholders' equity$ 595,344$ 410,609
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
 WEBSITEwww.bicycletherapeutics.com
 EMPLOYEES236

Bicycle Therapeutics Ltd Frequently Asked Questions


What is the ticker symbol for Bicycle Therapeutics Ltd? What does BCYC stand for in stocks?

BCYC is the stock ticker symbol of Bicycle Therapeutics Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bicycle Therapeutics Ltd (BCYC)?

As of Thu Mar 28 2024, market cap of Bicycle Therapeutics Ltd is 1.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCYC stock?

You can check BCYC's fair value in chart for subscribers.

What is the fair value of BCYC stock?

You can check BCYC's fair value in chart for subscribers. The fair value of Bicycle Therapeutics Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bicycle Therapeutics Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCYC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bicycle Therapeutics Ltd a good stock to buy?

The fair value guage provides a quick view whether BCYC is over valued or under valued. Whether Bicycle Therapeutics Ltd is cheap or expensive depends on the assumptions which impact Bicycle Therapeutics Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCYC.

What is Bicycle Therapeutics Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Mar 28 2024, BCYC's PE ratio (Price to Earnings) is -5.85 and Price to Sales (PS) ratio is 39.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCYC PE ratio will change depending on the future growth rate expectations of investors.